Karsten Bamminger, MSc
Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: PHD Student
karsten.bamminger@meduniwien.ac.at
Keywords
Biomarkers, Pharmacological; Positron-Emission Tomography; Programmed Cell Death 1 Receptor
Research interests
My research focuses primarily on the development of PET tracers for the PD-1/PD-L1 immune checkpoint. The ultimate goal is to achieve a better patient stratifcation in the context of anti-cancer immunotherapy and to improve therapy respone and survial.
Selected publications
- Tournier, N. et al., 2019. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 60(7), pp.985–991. Available at: http://dx.doi.org/10.2967/jnumed.118.219972.
- Pichler, V. et al., 2019. Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharmacy and Chemistry, 4(1). Available at: http://dx.doi.org/10.1186/s41181-019-0083-2.
- Ghavami, M. et al., 2021. Radiolabeled HER2-directed exosomes exhibit improved cell targeting and specificity. Nanomedicine, 16(7), pp.553–567. Available at: http://dx.doi.org/10.2217/nnm-2020-0408.
- Bauer, M. et al., 2021. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 23(2), pp.180–185. Available at: http://dx.doi.org/10.1007/s11307-021-01582-4.
- Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics, 109(3), pp.754–761. Available at: http://dx.doi.org/10.1002/cpt.2052.